{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:35:55Z","timestamp":1772134555701,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2003,6,29]],"date-time":"2003-06-29T00:00:00Z","timestamp":1056844800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Biotechnol"],"published-print":{"date-parts":[[2003,8]]},"DOI":"10.1038\/nbt843","type":"journal-article","created":{"date-parts":[[2003,6,27]],"date-time":"2003-06-27T10:06:11Z","timestamp":1056708371000},"page":"885-890","source":"Crossref","is-referenced-by-count":219,"title":["Nanoparticles for the delivery of genes and drugs to human hepatocytes"],"prefix":"10.1038","volume":"21","author":[{"given":"Tadanori","family":"Yamada","sequence":"first","affiliation":[]},{"given":"Yasushi","family":"Iwasaki","sequence":"additional","affiliation":[]},{"given":"Hiroko","family":"Tada","sequence":"additional","affiliation":[]},{"given":"Hidehiko","family":"Iwabuki","sequence":"additional","affiliation":[]},{"given":"Marinee KL","family":"Chuah","sequence":"additional","affiliation":[]},{"given":"Thierry","family":"VandenDriessche","sequence":"additional","affiliation":[]},{"given":"Hideki","family":"Fukuda","sequence":"additional","affiliation":[]},{"given":"Akihiko","family":"Kondo","sequence":"additional","affiliation":[]},{"given":"Masakazu","family":"Ueda","sequence":"additional","affiliation":[]},{"given":"Masaharu","family":"Seno","sequence":"additional","affiliation":[]},{"given":"Katsuyuki","family":"Tanizawa","sequence":"additional","affiliation":[]},{"given":"Shun'ichi","family":"Kuroda","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2003,6,29]]},"reference":[{"key":"BFnbt843_CR1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/38410","volume":"389","author":"IM Verma","year":"1997","unstructured":"Verma, I.M. & Sonia, N. Gene therapy: promises, problems, and prospects. Nature 389, 239\u2013242 (1997).","journal-title":"Nature"},{"key":"BFnbt843_CR2","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/nm0296-144","volume":"2","author":"T Friedmann","year":"1996","unstructured":"Friedmann, T. Human gene therapy: an immature genie, but certainly out of the bottle. Nat. Med. 2, 144\u2013147 (1996).","journal-title":"Nat. Med."},{"key":"BFnbt843_CR3","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1182\/blood.V100.3.813","volume":"100","author":"T VandenDriessche","year":"2002","unstructured":"VandenDriessche, T. et al. Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. Blood 100, 813\u2013822 (2002).","journal-title":"Blood"},{"key":"BFnbt843_CR4","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1182\/blood-2002-03-0823","volume":"101","author":"MK Chuah","year":"2003","unstructured":"Chuah, M.K. et al. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors. Blood 101, 1734\u20131743 (2003).","journal-title":"Blood"},{"key":"BFnbt843_CR5","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1126\/science.294.5547.1640","volume":"294","author":"E Marshal","year":"2001","unstructured":"Marshal, E. Viral vectors still pack surprises. Science 294, 1640 (2001).","journal-title":"Science"},{"key":"BFnbt843_CR6","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1126\/science.286.5448.2244","volume":"286","author":"E Marshal","year":"1999","unstructured":"Marshal, E. Gene therapy death prompts review of adenovirus vector. Science 286, 2244\u20132245 (1999).","journal-title":"Science"},{"key":"BFnbt843_CR7","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/S0140-6736(02)11290-6","volume":"360","author":"RH Buckley","year":"2002","unstructured":"Buckley, R.H. Gene therapy for SCID\u2014a complication after remarkable progress. Lancet 360, 1185\u20131186 (2002).","journal-title":"Lancet"},{"key":"BFnbt843_CR8","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/72576","volume":"18","author":"JL Fox","year":"2000","unstructured":"Fox, J.L. Investigation of gene therapy begins. Nat. Biotechnol. 18, 143\u2013144 (2000).","journal-title":"Nat. Biotechnol."},{"key":"BFnbt843_CR9","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1128\/JVI.52.2.396-402.1984","volume":"52","author":"KH Heermann","year":"1984","unstructured":"Heermann, K.H. et al. Large surface proteins of hepatitis B virus containing the pre-S sequence. J. Virol. 52, 396\u2013402 (1984).","journal-title":"J. Virol."},{"key":"BFnbt843_CR10","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/0378-1119(89)90232-1","volume":"78","author":"S Kuroda","year":"1989","unstructured":"Kuroda, S., Itoh, Y., Miyazaki, T., Otaka-Imai, S. & Fujisawa, Y. Efficient expression of genetically engineered hepatitis B virus surface antigen P31 proteins in yeast. Gene 78, 297\u2013308 (1989).","journal-title":"Gene"},{"key":"BFnbt843_CR11","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/0264-410X(90)90044-M","volume":"8","author":"Y Fujisawa","year":"1990","unstructured":"Fujisawa, Y., Kuroda, S., Van Eerd, P.M., Schellekens, H. & Kakinuma, A. Protective efficacy of a novel hepatitis B vaccine consisting of M (pre-S2+S) protein particles (a third generation vaccine). Vaccine 8, 192\u2013198 (1990).","journal-title":"Vaccine"},{"key":"BFnbt843_CR12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/0264-410X(91)90148-Y","volume":"9","author":"S Kuroda","year":"1991","unstructured":"Kuroda, S., Fujisawa, Y., Iino, S., Akahane, Y. & Suzuki, H. Induction of protection level of anti-pre-S2 antibodies in humans immunized with a novel hepatitis B vaccine consisting of M (pre-S2+S) protein particles (a third generation vaccine). Vaccine 9, 163\u2013169 (1991).","journal-title":"Vaccine"},{"key":"BFnbt843_CR13","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/S0021-9258(18)46039-5","volume":"267","author":"S Kuroda","year":"1992","unstructured":"Kuroda, S., Otaka, S., Miyazaki, T., Nakao, M. & Fujisawa, Y. Hepatitis B virus envelope L protein particles, synthesis and assembly in Saccharomyces cerevisiae, purification and characterization. J. Biol. Chem. 267, 1953\u20131961 (1992).","journal-title":"J. Biol. Chem."},{"key":"BFnbt843_CR14","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1016\/S0264-410X(01)00017-2","volume":"19","author":"T Yamada","year":"2001","unstructured":"Yamada, T. et al. Physicochemical and immunological characterization of hepatitis B virus envelope particles exclusively consisting of the entire L (pre-S1+pre-S2+S) protein. Vaccine 19, 3154\u20133163 (2001).","journal-title":"Vaccine"},{"key":"BFnbt843_CR15","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1128\/JVI.32.3.796-802.1979","volume":"32","author":"PL Marion","year":"1979","unstructured":"Marion, P.L., Salazar, F.H., Alexander, J.J. & Robinson, W.S. Polypeptides of hepatitis B virus surface antigen produced by a hepatoma cell line. J. Virol. 32, 796\u2013802 (1979).","journal-title":"J. Virol."},{"key":"BFnbt843_CR16","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/0092-8674(86)90663-X","volume":"46","author":"AR Neurath","year":"1986","unstructured":"Neurath, A.R., Kent, S.B., Stick, N. & Parker, K. Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Cell 46, 429\u2013436 (1986).","journal-title":"Cell"},{"key":"BFnbt843_CR17","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1128\/JVI.73.3.2052-2057.1999","volume":"73","author":"J Le Seyec","year":"1999","unstructured":"Le Seyec, J., Chouteau, P., Cannie, I., Guguen-Guillouzo, C. & Gripon, P. Infection process of the hepatitis B virus depends on the presence of a defined sequence in the pre-S1 domain. J. Virol. 73, 2052\u20132057 (1999).","journal-title":"J. Virol."},{"key":"BFnbt843_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0168-1656(88)90064-8","volume":"8","author":"M Kobayashi","year":"1988","unstructured":"Kobayashi, M. et al. Recombinant hepatitis B virus surface antigen carrying the pre-S2 region derived from yeast: purification and characterization. J. Biotechnol. 8, 1\u201322 (1988).","journal-title":"J. Biotechnol."},{"key":"BFnbt843_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/1521-2254(200101\/02)3:1<3::AID-JGM167>3.0.CO;2-H","volume":"3","author":"MK Chuah","year":"2001","unstructured":"Chuah, M.K. et al. Gene therapy for hemophilia. J. Gene Med. 3, 3\u201320 (2001).","journal-title":"J. Gene Med."},{"key":"BFnbt843_CR20","doi-asserted-by":"publisher","first-page":"301","DOI":"10.2174\/1566523013348508","volume":"1","author":"T VandenDriessche","year":"2001","unstructured":"VandenDriessche, T., Collen, D. & Chuah, M.K.L. Viral vector-mediated gene therapy for hemophilia. Curr. Gene Ther. 1, 301\u2013305 (2001).","journal-title":"Curr. Gene Ther."},{"key":"BFnbt843_CR21","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1089\/10430340252769770","volume":"13","author":"A Follenzi","year":"2002","unstructured":"Follenzi, A., Sabatino, G., Lombardo, A., Boccaccio, C. & Naldini, L. Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. Hum. Gene Ther. 13, 243\u2013260 (2002).","journal-title":"Hum. Gene Ther."},{"key":"BFnbt843_CR22","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/0168-1656(92)90100-N","volume":"23","author":"Y Itoh","year":"1992","unstructured":"Itoh, Y., Kuroda, S., Miyazaki, T., Otaka, S. & Fujisawa, Y. Identification of polymerized-albumin receptor domain in the pre-S2 region of hepatitis B virus surface antigen M protein. J. Biotechnol. 23, 71\u201382 (1992).","journal-title":"J. Biotechnol."},{"key":"BFnbt843_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0168-1656(02)00105-0","volume":"99","author":"KR Smith","year":"2002","unstructured":"Smith, K.R. Gene transfer in higher animals: theoretical considerations and key concepts. J. Biotechnol. 99, 1\u201322 (2002).","journal-title":"J. Biotechnol."},{"key":"BFnbt843_CR24","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/sj.gt.3300870","volume":"6","author":"H Ishikawa","year":"1999","unstructured":"Ishikawa, H. et al. Utilization of variant-type of human \u03b1-fetoprotein promoter in gene therapy targeting for hepatocellular carcinoma. Gene Ther. 6, 465\u2013470 (1999).","journal-title":"Gene Ther."},{"key":"BFnbt843_CR25","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/0140-6736(90)91874-A","volume":"336","author":"WF Carman","year":"1990","unstructured":"Carman, W.F. et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 336, 325\u2013329 (1990).","journal-title":"Lancet"},{"key":"BFnbt843_CR26","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1099\/0022-1317-78-10-2639","volume":"78","author":"HL Chiou","year":"1997","unstructured":"Chiou, H.L., Lee, T.S., Kuo, J., Mau, Y.C., and Ho, M.S. Altered antigenicity of 'a' determinant variants of hepatitis B virus. J. Gen. Virol. 78, 2639\u20132645 (1997).","journal-title":"J. Gen. Virol."},{"key":"BFnbt843_CR27","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/S0264-410X(97)00080-7","volume":"15","author":"R del Canho","year":"1997","unstructured":"del Canho, R. et al. Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982\u20131992: protective efficacy and long-term immunogenicity. Vaccine 15, 1624\u20131630 (1997).","journal-title":"Vaccine"},{"key":"BFnbt843_CR28","doi-asserted-by":"publisher","first-page":"7957","DOI":"10.1073\/pnas.85.21.7957","volume":"85","author":"ML Michel","year":"1988","unstructured":"Michel, M.L. et al. Induction of anti-human immunodeficiency virus (HIV) neutralizing antibodies in rabbits immunized with recombinant HIV-hepatitis B surface antigen particles. Proc. Natl. Acad. Sci. USA 85, 7957\u20137961 (1988).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnbt843_CR29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nm0202-121","volume":"8","author":"W Arap","year":"2002","unstructured":"Arap, W. et al. Steps toward mapping the human vasculature by phage display. Nat. Med. 8, 121\u2013127 (2002).","journal-title":"Nat. Med."},{"key":"BFnbt843_CR30","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/BF01053281","volume":"19","author":"J Yoshida","year":"1994","unstructured":"Yoshida, J., Mizuno, M. & Yagi, K. Efficient transfection of human interferon-\u03b2 gene to human glioma cells by means of cationic multilamellar liposomes coupled with a monoclonal antibody. J. Neurooncol. 19, 269\u2013274 (1994).","journal-title":"J. Neurooncol."},{"key":"BFnbt843_CR31","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/0923-2516(96)80588-7","volume":"146","author":"N Sonveaux","year":"1995","unstructured":"Sonveaux, N., Thines, D. & Ruysschaert, J.M. Characterization of the HBsAg particle lipid membrane. Res. Virol. 146, 43\u201351 (1995).","journal-title":"Res. Virol."},{"key":"BFnbt843_CR32","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/(SICI)1096-9098(199903)70:3<145::AID-JSO1>3.0.CO;2-O","volume":"70","author":"Y Murayama","year":"1999","unstructured":"Murayama, Y. et al. Cell-specific expression of the diphtheria toxin A-chain coding sequence under the control of the upstream region of the human \u03b1-fetoprotein gene. J. Surg. Oncol. 70, 145\u2013149 (1999).","journal-title":"J. Surg. Oncol."},{"key":"BFnbt843_CR33","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0378-1119(96)00753-6","volume":"189","author":"S Inoue","year":"1997","unstructured":"Inoue, S., Ogawa, H., Yasuda, K., Umesono, K. & Tsuji, F.I. A bacterial cloning vector using a mutated Aequorea green fluorescent protein as an indicator. Gene 189, 159\u2013162 (1997).","journal-title":"Gene"}],"container-title":["Nature Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nbt843.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nbt843","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nbt843.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T15:56:48Z","timestamp":1684425408000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nbt843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,6,29]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2003,8]]}},"alternative-id":["BFnbt843"],"URL":"https:\/\/doi.org\/10.1038\/nbt843","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1014727.194564","asserted-by":"object"}]},"ISSN":["1087-0156","1546-1696"],"issn-type":[{"value":"1087-0156","type":"print"},{"value":"1546-1696","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,6,29]]}}}